Compared to traditional polarisers that are slow in the MRI setting, the NVision Polarizer is fast and easy-to-use. Credit: My Ocean Production/ shutterstock.com.

NVision Imaging has secured $30m in funding in a Series A round, with an additional $19.5m from the German Government, for advancing the development and deployment of the NVision Polarizer for cancer treatment.

Playground Global led the round, which was also joined by return investors b-to-v and new investors Entree Capital, Pathena Investments, Lauder Family, Sparkassenkapital Ulm and ES Kapital.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

These investors brought their total investment to $35m, excluding the government funds.

Existing MRIs identify a cancer therapy’s slow-changing effects at the tissue level, which can take months to expose from the beginning of the treatment.

Metabolic MRIs can spot early changes in major metabolic pathways at the cellular level, which can reveal within days from the commencement of treatment.

See Also:

These metabolic MRIs depend on polarisation, which facilitates the measurement of natural metabolites.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Compared to traditional polarisers that are slow and difficult to use in the MRI setting, the NVision Polarizer is fast and easy to use.

Leveraging a new parahydrogen-induced polarisation (PHIP) technique, NVision is using advances in quantum physics, chemistry and engineering to improve metabolic MRIs.

NVision already formed a collaboration with Siemens Healthineers to deploy NVision Polarizer systems at more than 50 cancer centres worldwide by 2025.

The company plans preclinical use of quantum metabolic polarisers this year. In the coming years, the funding will be used to deploy the technology for human care.

NVision Imaging CEO Dr Sella Brosh said: “The impact that this technology will have on medicine is monumental.

“With more accessibility to this kind of technology and giving doctors more time to choose the right therapy for treatment, we can significantly improve a patient’s chance of recovery while not subjecting them to toxic treatments that hurt more than they help.”